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Aim To validate Systemic Lupus International Collaborat-
ing Clinics (SLICC)-12 and American College of Rheumatol-
ogy (ACR)-97 classification criteria on a patient cohort from 
the University Hospital Center Zagreb.
Methods This retrospective study, conducted from 2014 
to 2016, involved 308 patients with systemic lupus erythe-
matosus (SLE) (n = 146) and SLE-allied conditions (n = 162). 
Patients’ medical charts were evaluated by an expert rheu-
matologist to confirm the clinical diagnosis, regardless of 
the number of the ACR-97 criteria met. Overall sensitivity 
and specificity, as well as the sensitivity and specificity ac-
cording to disease duration, were compared between ACR-
97 and SLICC-12 classifications. Predictive value for SLE for 
both classifications was assessed using logistic regression 
and receiver operating characteristic (ROC) curves.
Results The SLICC-12 criteria had significantly higher sen-
sitivity in early disase, which increased with disease dura-
tion. The ACR-97 criteria had higher specificity. The speci-
ficity of the SLICC-12 criteria was low and decreased with 
disease duration. Regression analysis demonstrated the 
superiority of the SLICC-12 classification criteria over the 
ACR-97 criteria, with areas under the ROC curve of 0.801 
and 0.780, respectively.
Conclusion Although the SLICC-12 criteria were superi-
or to the ACR-97 and were more sensitive for diagnosing 
early SLE, their specificity in our population was too low. 
The sensitivity of the SLICC-12 classification is increased by 
better defined clinical features within each criterion. Our 
results contribute to the current initiative for developing 
new criteria for SLE.
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Systemic lupus erythematosus (SLE) is a chronic autoim-
mune disease characterized by the production of autoan-
tibodies and immune complexes, and their deposition 
into different tissues. Its etiology is still unclear, with ge-
netic and environmental factors contributing to disease 
development (1-3). SLE has a relapsing-remitting course, 
and disease damage accumulates over time. Given that 
the period from the disease onset to permanent damage 
can be long, SLE is hard to diagnose in its early stages. It is 
even more difficult to classify patients using classification 
criteria of the American College of Rheumatology (ACR). 
Therefore, in a clinical setting, substitute entities such as 
incomplete lupus erythematosus (ILE), preclinical lupus, 
or latent lupus are often mentioned when describing pa-
tients whose clinical and laboratory findings suggest SLE 
but who meet fewer than 4 ACR criteria (4-6).
Advances in understanding of pathogenetic mechanisms 
require the redefinition and validation of classification cri-
teria. Redefined criteria would encompass some of the 
patients with undefined disease and enable more thor-
ough monitoring of the disease course and more prompt 
therapy introduction. In rheumatology, the development 
of classification criteria is challenging due to the lack of a 
clinical, etiopathogenetic, or diagnostic gold standard. In-
stead, the gold standard remains the expert rheumatolo-
gist’s opinion (7,8).
ACR published the first, preliminary, criteria for SLE in 1971, 
which were revised in 1982 and later validated. The second 
revision from 1997 (ACR-97), although unvalidated, has 
been the most widely used criteria set to date (9-13) (Table 
1). The prerequisite for enrolling patients in clinical studies 
is cumulative attainment of any 4 of the 11 ACR criteria. 
Despite their high sensitivity (>85%) and specificity (>95%) 
in longstanding SLE, their sensitivity in early disease can be 
significantly lower (14-16). Furthermore, some organ sys-
tems are overrepresented (eg, 4 criteria attributed to skin 
and mucosa), with equal contribution of every criterion 
to the diagnosis regardless of its specificity and sensitiv-
ity. Clinical experience and previous studies have shown 
greater statistical significance of certain criteria, such as re-
nal impairment, discoid rash, or cytopenias (14,17,18). Dif-
ferent statistical methods have been employed with the 
purpose to develop optimal classification rule (19-22). So-
mogy et al validated the ACR criteria on a patient cohort 
TABle 1. Difference between Systemic lupus International Collaborating Clinics (SlICC)-12 and American College of Rheumatology 
(ACR)-97 classification criteria*
SlICC 2012 ACR 1997
 ACL (maculopapulous, psoriasiform, bullous, toxic epidermal necrolysis)
CCL (hypertrophic, mucosal, panniculitis, chilblain, LE tumidus, discoid/
lichen planus overlap)
Nonscarring alopecia
Oral ulcers (also ex anamnesis)
Joint-line tenderness, morning stiffness, also erosive
Pleuritis, pericarditis
Renal disorder (daily OR spot urine – protein/creatinine ratio, 
24h proteinuria >0.5 g, cellular casts, red blood cell casts)
Seizures, psychosis, M.multiplex, myelitis, periph/cran neuropathy, 
acute confusional state
Hemolytic anemia
Leukopenia (<4000 mm3)/Lymphopenia (<1000 mm3) – ONCE
Thrombocytopenia <100,000/mm3 – ONCE
Malar rash
 Discoid rash
 Photosensitivity
 Oral ulcers (present at check-up)
 Arthritis (non-erosive)
 Serositis (pleuritis, pericarditis)
 Renal disorder (daily protein/creatinine ratio, 24h 
proteinuria >0.5g, cellular casts)
 Psychosis, grand mal epilepsy
 Hemolytic anemia OR
on ≥2 occasions: Leukopenia <4000/mm3 OR Lymphopenia 
<1000/mm3 OR Thrombocytopenia <100 000/mm3
Anti-dsDNA
Anti-Sm
ACL Ig-A/M/G, LAC, RPR, anti-β2 GPI (Ig-A/M/G)
Low C3, C4, CH 50
Direct Coombs+ (absence of hemolytic anemia)
ANA
Anti-dsDNA OR
Anti-Sm OR
ACL IgG/IgM, LAC, RPR
ANA
*ACl –acute cutaneous lupus; CCl – chronic cutaneous lupus; le – lupus erythematosus; dsDNA – double stranded DNA; anti-Sm – anti-Smith 
antibody; aCl – anticardiolipins; lAC – lupus anticoagulant; RPR – rapid plasma reagin test; anti-β2 GPI – anti-β2-glycoprotein I; C3 – complement 
component 3; C4 – complement component 4; CH50 – 50% hemolytic complement activity; ANA – anti-nuclear antibody.
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treated at the University Hospital Centre (UHC) Zagreb in 
1993 (18), demonstrating substantial differences in the 
weight of individual criteria. Cerovec et al reported the 
prevalence of ACR-97 criteria in patients treated at UHC 
Zagreb (23).
Systemic Lupus International Collaborating Clinics (SLICC) 
group in 2012 published a new classification based on 
revised ACR-97 criteria, comprising 17 criteria (11 clinical 
and 6 immunologic, Table 1) (14). The SLICC-12 classifica-
tion, more thoroughly defines each criterion, encompass-
es some of the typical mucocutaneous manifestations and 
neuropsychiatric symptoms omitted in the ACR-97 classi-
fication, alters arthritis definition, and significantly revises 
laboratory findings. SLICC-12 classification specifies that 
patients can be diagnosed with SLE if they meet 4 of the 17 
criteria with at least 1 immunologic and 1 clinical criterion. 
One of the most important improvements is that biopsy-
proven lupus nephritis with positive antinuclear antibody 
(ANA) and/or anti-double stranded DNA (dsDNA) is a suf-
ficient requirement to meet the SLE diagnosis.
The multi-annual revision of the SLE classification conduct-
ed by the SLICC was a two-step process consisting of cri-
teria derivation and criteria validation in two large patient 
groups. In the derivation group, the SLICC-12 classification 
showed greater sensitivity than the ACR-97 criteria, almost 
equal specificity, and had significantly fewer missclassifica-
tions. In the validation step there was no statistical differ-
ence between the two classifications (14).
Studies published to date have shown that the SLICC-12 
classification successfully recognizes patients with estab-
lished disease. Furthermore, the ACR-97 and SLICC-12 cri-
teria are complementary in discriminating SLE from ILE 
with a milder disease course (24,25). The first studies have 
reported higher sensitivity of the SLICC-12 classification 
compared with the ACR-97 criteria in the early stages of 
SLE (6,26). The SLICC-12 criteria need to be further evalu-
ated and validated on new cohorts to investigate if they 
are superior to ACR-97 classification.
Division of Clinical immunology and Rheumatology, UHC 
Zagreb, Croatia, is a national referral center for SLE and lu-
pus-allied diseases. The Division serves patients from all 
over the country, predominantly from northwestern Cro-
atia. The aim of this research was (i) to validate the new 
SLICC-12 classification criteria in our patient cohort, in a 
real-life setting, (ii) to compare the ACR-97 and SLICC-12 
criteria and assess if SLICC-12 criteria recognize patients in 
early stages of SLE (<5 years) better than the ACR-97 crite-
ria, and (iii) to form a well-defined patient cohort with SLE 
for future research using the SLICC-12 criteria with the pur-
pose of distinguishing patients with early-onset SLE.
PATIeNTS AND MeTHoDS
Patients
This retrospective study comprised 308 patients treated 
at the Division’s outpatient clinic. From 2010 to 2012, a 
complete patient database at the Division of Clinical im-
munology and Rheumatology was reviewed and patient 
documentation assessed. The database contained data 
on approximately 30 000 patients, 2000 of whom had SLE, 
SLE-allied, and other unspecified conditions (collagenosis, 
antiphospholipid syndrome [APS], Sy Sjögren, mixed con-
nective tissue disease [MCTD], undifferentiated connec-
tive tissue disease [UCTD], discoid lupus erythematosus 
[DLE], Sy Raynaud, glomerulonephritis, overlap syndrome, 
oligoarthritis HLAA1B8DR3 positive, lymphopenia). Out of 
these 2000 patients, 527 patients were defined, followed 
up, and clinically diagnosed with SLE or suspected SLE. 
They were the starting point for conducting this research. 
The study also included 201 new patients with SLE or po-
tential SLE who started their follow up at the Department 
from 2012 to 2016. The patients with insufficient medical 
data or without regular follow ups were excluded. Final-
ly, the patients were divided in two groups: 146 patients 
with established SLE (diagnosed by rheumatologist) and 
162 patients with SLE-allied conditions. The criterion for 
the study inclusion was not the number of classification 
criteria fulfilled, but the clinical diagnosis determined by 
the expert rheumatologist, which remains the gold stan-
dard for diagnosing SLE.
Patients who had to undergo kidney biopsy for lupus ne-
phritis staging have signed an informed consent, which 
is a standard procedure at the Clinic. The study was ap-
proved by the Ethics Committee of the University Hospital 
Center Zagreb.
Methods
All of the patient records were reevaluated by expert rheu-
matologist in order to determine if they agree with the 
diagnosis. For every patient, a check-list of SLE-related 
features was filled out. The association between clinical 
diagnosis and diagnosis generated on the basis of both 
ACR-97 and SLICC-12 classification criteria was as-
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sessed. The overall sensitivity and specificity of ACR-97 and 
SLICC-12 classifications, as well as the sensitivity and speci-
ficity according to disease duration was calculated. The 
predictive value of every criterion in ACR-97 and SLICC-12 
classification was assesed using logistic regression analysis 
and receiver operating characteristic (ROC) curves.
Laboratory tests were carried out at the UHC Zagreb. 
ANA were determined by indirect immunofluorescence 
on Hep-2 cells (Euroimmun, Lübeck, Germany). Specific 
antibodies against dsDNA, histones, Sjögren-Syndrom-
related antigen A and B, Smith, U1-ribonucleoprotein, 
scleroderma-70, and histidyl-tRNA synthetase were de-
tected by fluorescent color-coded beads immunotest 
– Luminex (AtheNA-ANA multiplex assay, Zeus Scientif-
ic Inc., Branchburg, NJ, USA). Autoantibodies against dif-
ferent phospholipid antigen determinants (IgM and IgG 
anticardiolipin antibodies and IgG anti- β2 glycoprotein 
I antibodies) were determined by enzyme-linked immu-
nosorbent assay (Orgentec Diagnostics GmbH, Mainz 
and Euroimmun, Lübeck, Germany). Finally, hemolytc ac-
tivity of the classical activation pathway was quantified 
by determining serum dilution causing lysis of 50% sheep 
erythrocytes covered with sheep IgM antibodies (CH50, 
in house method).
Statistical analysis
Simple descriptive statistics was computed in Microsoft 
Excel 2010 (Microsoft Corporation, Redmond, WA, USA), 
while univariate and multivariate logistic regression and 
stepwise procedure were performed in SAS (SAS Institute, 
Cary, NC, USA) with the purpose to determine the best pre-
dictive models (27). A 5% level of significance (type I er-
ror) was considered significant. Differences in proportions 
were assessed using the test of proportions.
ReSulTS
Disease duration and sex distribution
Mean disease duration from the time of first symptoms’ 
onset was 11 ± 7 years, while the mean disease duration 
from the time of diagnosis was 10 ± 7 years. The relatively 
short period needed to diagnose SLE could be attributed 
to prompt and effective diagnostic procedure in a high-
ly specialized tertiary institution. Our cohort consisted of 
279/308 (90.6%) female patients, which is the expected sex 
distribution in SLE patients (1-3). Sex distribution was al-
most equal in two patient-groups: 132 (90.4%) women in 
the SLE-group and 147 (90.7%) women in the NSLE-group. 
Mean age of all patients was 51 ± 14 years (range 20-88). 
Male patients had somewhat lower age (mean 48 ± 13) 
than female patients (mean 52 ± 15). The mean age at the 
first visit was the same as the age at the time of diagnosis 
(41 ± 14 years).
Prevalence of SlICC-12 and ACR-97 classification criteria
The prevalence of both SLICC-12 and ACR-97 classification 
criteria was assessed in both SLE and NSLE patient group 
(Tables 2 and 3). Since NSLE patients have diseases similar 
to SLE, with overlapping clinical symptoms, we identified 
the criteria that were significantly more represented in the 
SLE-group. As expected, all of the criteria from the SLICC-
12 and ACR-97 classification were more prevalent in the 
SLE-group. Among SLICC-12 criteria, significantly more 
prevalent were renal impairment (11.6% in SLE-group vs 
TABle 2. Prevalence of the ACR-97 criteria in Sle (N = 146) and NSle (N = 162) patient groups*
ACR criteria Total, n (%) Sle, n (%) NSle, n (%) P (Sle vs NSle)
Photosensitivity  53 (17.2)  27 (18.5)  26 (16)  0.562
Butterfly rash  49 (15.9)  26 (17.8)  23 (14.2)  0.389
Discoid lupus  37 (12)  18 (12.3)  19 (11.7)  0.871
Oral ulcerations   8 (2.6)   4 (2.7)   4 (2.5)  0.912
Arthritis  80 (26)  39 (26.7)  41 (25.3)  0.780
Serositis  10 (3.2)   8 (5.5)   2 (1.2)  0.033
Renal impairment  24 (7.8)  18 (12.3)   6 (3.7)  0.005
NPSLE   9 (2.9)   6 (4.1)   3 (1.8)  0.229
Hematologic criterion 144 (46.7)  69 (47.3)  75 (46.3)  0.860
Immunologic criterion 186 (60.4) 117 (80.1)  69 (42.3) <0.0001
ANA 275 (89.3) 138 (94.5) 137 (84.6)  0.005
*SlICC-12 – Systemic lupus International Collaboration Clinics classification from 2012; ACR-97 – American College of Rheumatology classification 
from 1997; NSle – nonSle; patients with Sle-allied conditions; NPSle – neuropsychiatric lupus erythematosus; ANA – anti-nuclear antibody.
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3.7% in NSLE-group, P = 0.008), serositis (6.9% in SLE-group 
vs 1.2% in NSLE-group, P = 0.010), and synovitis (39.7% in 
SLE-group vs 28.5% in NSLE-group, P = 0.038). Further-
more, each of the 6 SLICC-12 immunologic criteria was 
significantly more prevalent in the SLE-group (Table 3). 
Among ACR-97 criteria, significantly more prevalent were 
renal impairment (12.3% in SLE-group vs 3.7% in NSLE-
group, P = 0.005), serositis (5.5% in SLE-group vs 1.2% in 
NSLE-group, P = 0.033), immunologic criterion (80.1% in 
SLE-group vs 42.3% in NSLE-group, P < 0.0001), and ANA 
antibodies (94.5% in SLE-group vs 84.6% in NSLE-group, 
P = 0.005).
Sensitivity and specificity of SlICC-12 and ACR-97 
criteria by disease duration
In order to assess if SLICC-12 classification was superior to 
ACR-97 classification in earlier stages of SLE, we distrib-
uted the patients into groups according to disesase dura-
tion: the early disease group (disease onset max. 5 years 
TABle 3. Prevalence of the SlICC-12 criteria in Sle (N = 146) and NSle (N = 162) patient groups*
SlICC criteria Total, n (%) Sle, n (%) NSle, n (%) P (Sle vs NSle)
ACL 100 (32.5)  48 (33)  52 (32)  0.851
CCL  34 (11)  17 (11.6)  17 (10.5)  0.758
Alopecia  23 (7.5)  12 (8.2)  11 (6.8)  0.641
Oral ulcerations  12 (3.9)   7 (4.8)   5 (3)  0.411
Synovitis 104 (33.7)  58 (39.7)  46 (28.5)  0.038
Serositis  12 (3.9)  10 (6.9)   2 (1.2)  0.010
Renal impairment  23 (7.5)  17 (11.6)   6 (3.7)  0.008
NPSLE  40 (12.9)  21 (14.4)  19 (11.7)  0.482
Hemolytic anemia   7 (2.3)   7 (4.58)   0  N/A
Leuko/lymphopenia 130 (42.2)  63 (43.2)  67 (41.4)  0.749
Thrombocytopenia  37 (12)  18 (12.3)  19 (11.7)  0.871
ANA 275 (89.3) 136 (92.5) 139 (85.8)  0.030
Anti-dsDNA 155 (50) 103 (70.5)  52 (32.1) <0.0001
Anti-Sm  37 (12)  23 (15.7)  14 (8.6)  0.055
APA 103 (33.4)  65 (44.5)  38 (23.5)  0.0001 
Complement 140 (45.4)  76 (52)  64 (39.5)  0.028
Coombs test  10 (3.3)   8 (5.5)   2 (1.2)  0.033
*SlICC-12 – Systemic lupus International Collaboration Clinics classification from 2012; ACR-97 – American College of Rheumatology classification 
from 1997; NSle – nonSle; patients with Sle-allied conditions; ACl –acute cutaneous lupus; CCl – chronic cutaneous lupus; NPSle – neuropsychi-
atric lupus erythematosus; ANA – anti-nuclear antibody; dsDNA – double stranded DNA; anti-Sm – anti-Smith antibody; APA – anti-phospholipid 
antibody; N/A – not applicable.
FIGuRe 1. Sensitivity (A) and specificity (B) of Systemic lupus International Collaborating Clinics (SlICC)-12 (red) and American Col-
lege of Rheumatology (ACR)-97 classification criteria (blue) by disease duration.
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FIGuRe 2. Receiver-operating characteristic curves for Systemic lupus International Collaborating Clinics (SlICC)-12 (likelihood 
ratio = 87.088, degrees of freedom = 17, P < 0.001) (A) and American College of Rheumatology (ACR)-97 criteria (likelihood ra-
tio = 83.283, degrees of freedom = 13, P < 0.001) (B). RoC – receiver-operating characteristic.
FIGuRe 3. Receiver-operating characteristic curves for Systemic lupus International Collaborating Clinics (SlICC)-12 criteria – clinical 
(likelihood ratio = 11.161, degrees of freedom = 1, P = 0.0008) (A) vs immunologic (likelihood ratio = 44.138, degrees of freedom = 1, 
P < 0.0001) (B). RoC – receiver-operating characteristic.
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ago) and the remaining groups by five-year periods of 
disease duration (5-10 years, 10-15 years, 15-20 years, 20-
25 years, and 25-30 years). In the early-disease group, the 
SLICC-12 criteria had 74% sensitivity and a low specific-
ity of 58.5%. The sensitivity and specificity of the ACR-97 
criteria were 22.2% and 98.1%, respectively. The sensitiv-
ity of the SLICC-12 criteria increased with disease dura-
tion, while their specificity decreased. On the other hand, 
the low sensitivity of the ACR-97 criteria in the early SLE 
stage showed a slow, but stabile growth. Similarly, their 
specificity was high in all patient groups and increased 
to 100% in the long-standing, established disease (Figure 
1A and 1B)
TABle 4. logistic regression – the analysis of effects for ACR-97 criteria*
ACR-97 Criteria DF Wald χ2 P oR 95% CI c (multivariate analysis) = 0.7803 c (univariate analysis)
Butterfly rash 1  6.1690  0.0130  2.619 1.225-5.597 0.518
Discoid rash 1 10.5618  0.0012  4.469 1.840-11.743 0.503
Oral ulcers 1  1.1994  0.2734  2.263 0.467-14.739 0.501
Photosensitivity 1  5.2923  0.0214  2.354 1.135-4.880 0.512
Arthritis 1  1.6436  0.1998  1.523 0.801-2.897 0.507
Serositis 1  3.7244  0.0536  5.651 0.973-32.812 0.521
Renal disorder 1  7.0237  0.0080  4.170 1.450-11.988 0.543
NPSLE 1  2.6114  0.1061  4.009 0.744-21.601 0.511
Hematologic disorder 1  4.9577  0.0260  1.946 1.083-3.498 0.505
Immunologic disorder 1 43.4587 <0.0001 10.933 5.369-22.263 0.688
ANA 1  2.5167  0.1126  2.222 0.829-5.957 0.550
LR = 83.283, DF = 13, P < 0.0001
*ACR-97 – American College of Rheumatology classification from 1997; NPSle – neuropsychiatric lupus erythematosus; ANA – anti-nuclear antibody; 
lR – likelihood ratio; DF – degrees of freedom; oR – odds ratio; 95% CI – 95% confidence interval; c – area under the RoC curve.
TABle 5. logistic regression – the analysis of effects for SlICC-12 criteria*
Criteria DF Wald χ2 P oR 95% CI c (multivariate analysis) = 0.8017 c (univariate analysis)
ACL 1  2.6327 0.1047 1.615 0.905-2.883 0.502
CCL 1 11.9335 0.0006 4.845 1.979-11.862 0.506
Oral ulcers 1  0.9115 0.3397 2.090 0.460-9.487 0.505
Alopecia 1  0.1323 0.7161 0.830 0.304-2.264 0.507
Sinovitis 1  5.7563 0.0164 2.019 1.137-3.584 0.558
Serositis 1  2.2970 0.1296 3.576 0.688-18.576 0.528
Renal disorder 1  6.9346 0.0085 4.196 1.443-12.203 0.540
NPSLE 1  0.2949 0.5871 1.225 0.590-2.544 0.525
Hemolytic anemia 1  0.5408 0.4621 4.286 0.089-207.265 0.507
L/ly-penia 1  2.0488 0.1523 1.514 0.858-2.672 0.507
Thrombocytopenia 1  0.0582 0.8093 0.902 0.389-2.088 0.503
ANA 1  1.9760 0.1598 1.992 0.762-5.206 0.540
Anti-dsDNA 1 30.8423 <0.0001 5.131 2.881-9.139 0.695
Anti-Sm 1  0.1703 0.6798 0.830 0.342-2.011 0.536
APA 1  9.7391 0.0018 2.596 1.426-4.725 0.607
Complement 1  0.6989 0.4032 1.259 0.733-2.163 0.561
Coombs test 1  2.7419 0.0977 4.259 0.766-23.671 0.521
LR = 87.088, DF = 17, P < 0.0001
*SlICC-12 – Systemic lupus International Collaboration Clinics classification from 2012; ACl –acute cutaneous lupus; CCl – chronic cutaneous lupus; 
NPSle – neuropsychiatric lupus erythematosus; l – leukocyte; ly – lymphocyte; ANA – anti-nuclear antibody; dsDNA – double stranded DNA; anti-
Sm – anti-Smith antibody; APA – anti-phospholipid antibody; lR – likelihood ratio; oR – odds ratio; 95% CI – 95% confidence interval; c – area under 
the RoC curve.
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Regression analysis of SlICC-12 and ACR-97 
classification criteria
Using regression analysis, we tested the predictive value of 
classification criteria for diagnosing SLE in our patient co-
hort. Additionally, to select the best combination of classi-
fication criteria and to create the most adequate model for 
predicting SLE, we employed stepwise procedure.
Univariate analysis showed that the SLICC-12 classification 
was a better predictor of SLE than the ACR-97 criteria, with 
the areas under the ROC-curve (AUC)SLICC = 0.801 and AU-
CACR = 0.780 (Figures 2A and 2B). We found a moderate re-
lationship of the number of ACR-97 criteria with the SLE 
diagnosis, with AUC = 0.711. An increase in the total num-
ber of ACR-97 criteria by 1 increased the odds ratio (OR) 
for diagnosing SLE by almost 3 times (OR 2.916, 95% confi-
dence interval [CI] 1.085-4.078). The total number of SLICC-
12 criteria was a slightly better predictor for diagnosing 
SLE than the number of ACR-97 criteria, with AUC = 0.728. 
Interestingly, an increase in the number of SLICC-12 crite-
ria by 1 increased the OR for diagnosing SLE by almost 2 
times (OR 1.727, 95% CI 1.454-2.050). When we analyzed 
the clinical and immunologic SLICC criteria separately, im-
munologic criteria showed greater predictive value, with 
AUCimmun = 0.708 and AUCclin = 0.607 (Figures 3A and 3B) 
(Table 4 and Table 5).
Using stepwise procedure, we obtained the best predic-
tive models for SLE. Stepwise procedure for SLICC-12 clas-
sification generated a combination of 6 criteria: chronic 
cutaneous lupus, renal impairment, anti-dsDNA antibody, 
anti-cardiolipin antibody, β2-glycoprotein I, and a positive 
Coombs test. Taken together, these criteria had the best 
predictive value for SLE, with AUC = 0.770 (Figure 4). Step-
wise procedure for the ACR-97 classification generated a 
model containing butterfly rash, discoid rash, photosen-
sitivity, renal impairment, and immunologic disorder. The 
latter model was the best predictor of SLE in our patient 
cohort, with AUC = 0.740 (Figure 5).
FIGuRe 4. The best predictive model for systemic lupus 
erythematosus, generated by stepwise procedure from the 
Systemic lupus International Collaborating Clinics (SlICC)-12 
criteria, area under the receiver-operating characteristic (RoC) 
curve = 0.770. Step 0 – anti-dsDNA antibody, Step 1 – anti-
phospholipid antibodies, Step 2 – chronic cutaneous lupus, 
Step 3 – renal impairment, Step 4 – coombs test, Step 5 – anti-
β2-glycoprotein I.
FIGuRe 5. The best predictive model for systemic lupus erythe-
matosus, generated by stepwise procedure from the American 
College of Rheumatology (ACR)-97 criteria, area under the 
receiver-operating characteristic (RoC)curve = 0.735. Step 
0 – immunologic disorder, Step 1 – renal impairment, Step 2 
– discoid rash, Step 3 – butterfly rash, Step 4 – photosensitivity.
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DISCuSSIoN
Our results show the superiority of the SLICC-12 criteria and 
their somewhat greater predictive value for diagnosing SLE 
compared with the ACR-97 criteria, especially in the early 
disease stage. Better defined clinical features within each 
criterion contribute to higher sensitivity of the SLICC-12 
classification. Nevertheless, in our cohort, the specificity of 
SLICC-12 classification was too low and decreased with SLE 
duration. The ACR-97 classification showed higher specific-
ity than the SLICC-12 classification. Our results agree with 
the results of criteria validation by the SLICC group and 
other research, which have shown high specificity of the 
ACR-97 criteria in the established disease, with lower, but 
acceptable sensitivity (9,26,28,29). SLE diagnosis is hard to 
confirm due to its heterogeneous clinical presentation and 
slow accumulation of symptoms. Therefore, the ACR-97 
criteria do not have adequate sensitivity to recognize pa-
tients in the early disease stage. On the other hand, SLICC-
12 criteria have so far shown higher sensitivity than the 
ACR-97 in the early disease, as well as in milder SLE cases, 
in UCTD, and in juvenile SLE (24-26,29-34). Nevertheless, in 
our study, SLICC-12 classification often had lower specific-
ity than the ACR-97, which was also confirmed in the vali-
dation process by the SLICC group (14).
When we compared the two classifications in terms of 
disease duration, the greatest difference in sensitivity 
emerged in the early disease stage. These results agree 
with those from other reports. A study involving 2055 pa-
tients from Spanish and Portuguese registers (26) showed 
that the SLICC-12 criteria had significantly higher sensitiv-
ity than the ACR-97 criteria in the earlier disease stages 
and that their sensitivity increased with disease duration. 
In the long-standing disease, the sensitivity of the two 
classifications did not significantly differ (26). Studies on 
pediatric patients with SLE also showed higher sensitivity 
in the earlier disease stages and lower specificity (31-33). 
A study involving patients from a Swedish lupus register 
reported that SLICC-12 criteria had higher sensitivity (94% 
vs 90%), but a surprisingly low specificity (74%). The au-
thors recommend that a combination of the two criteria 
sets is used to define patients more precisely (28). Further-
more, research on 495 patients from 12 Japanese medical 
centers showed similar results: higher sensitivity (99% vs 
88%) and lower specificity of the SLICC-12 criteria com-
pared with the ACR-97 criteria (80% vs 85%) (35). In the 
Mexican population, fewer patients were missclassified 
when the ACR-97 criteria were used, with higher speci-
ficity and positive predictive value (36). This implies that 
the ACR-97 criteria are more reliable in a “real-life“ setting. 
A study conducted in Olmsted county (Minnesota, USA) 
showed a higher SLE incidence if the SLICC-12 criteria are 
used, mostly because of the added classification rule on 
biopsy-proven lupus nephritis along with positive ANA or 
anti-dsDNA antibodies (37).
Regression analysis in our patient cohort showed the su-
perioritiy of the SLICC-12 classification. The number of the 
SLICC-12 criteria met by a patient was more strongly as-
sociated with SLE diagnosis than the number of ACR-97 
criteria. Nevertheless, the increase in the number of the 
ACR-97 criteria met was more strongly associated with SLE. 
Univariate analysis showed a minor difference between 
the two classifications. In general, both criteria sets in our 
patient cohort showed significant association with SLE, 
with SLICC-12 classification being a slightly better predic-
tor. Multivariate analysis showed different predictive value 
of some criteria in the two classifications. The SLICC crite-
ria that most contributed to diagnosing SLE were chronic 
cutaneous lupus, synovitis, renal impairment, anti-dsDNA, 
and APL antibodies. On the other hand, ACR-97 criteria 
that most contributed to diagnosing SLE were acute cu-
taneous lupus (photosensitivity and butterfly rash), discoid 
lupus, serositis, renal impairment, hematologic, and immu-
nologic disorder. Acute cutaneous lupus in the new crite-
ria encompasses various manifestations that often overlap 
and, taken together, in our cohort did not show enough 
specificity for SLE. Therefore, they are not as represented 
as the often described malar rash and photosensitivity in 
the ACR-97 criteria. As opposed to earlier research (37), the 
two classifications did not significantly differ regarding re-
nal impairment in our cohort. Given that arthritis/synovitis 
is less strictly defined in SLICC-12 criteria, it emerged sig-
nificant in regression analysis, as well as the hematologic 
criterion of the ACR-97 classification, which incorporates 
a disorder in all three blood cell lineages. Although step-
wise procedure generated optimal criteria combinations 
for predicting SLE, the strongest predictor turned out to 
be the overall classification, regarding both SLICC-12 and 
ACR-97 classification. This is contradictory to the results 
of Mesa at al (38), who, also employing regression analy-
sis, reported that reduced models, rather than the whole 
classification, were better discriminators of SLE patients 
among unclear cases of MCTD. Al-Daabil et al (39) found 
that strong predictors of SLE were oral ulcerations, renal 
impairment, and anti-dsDNA antibodies. A study involv-
ing 110 patients with SLE from another tertiary center 
in Croatia reported a linear correlation of the number 
of SLICC-12 criteria and disease activity, while no 
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such correlation was reported for the ACR-97 criteria (40). 
Amezcua-Guerra et al (36) showed high positive and nega-
tive predictive values for both classifications, with higher 
specificity of the ACR-97 criteria for SLE.
Our study has several limitations. First, it was carried out in 
a single center and, therefore, may not account for the en-
tire population with SLE in Croatia. Nevertheless, our cen-
ter has a substantial number of SLE patients, from all parts 
of the country (predominantly northwestern). Second, a 
considerable number of patients (35%) in this study was in 
the early stage of the disease at the time of data collection. 
This could imply a milder disease in the overall sample. Still, 
taken together, all studies carried out so far, as well as this 
study, have shown overall a minor difference between the 
two classifications. SLICC-12 classification, despite its high 
sensitivity, wider range of incorporated clinical manifesta-
tions, and immunologic criteria, does not show significant 
supremacy in a real-life setting. This is largely due to the 
high specificity of the ACR-97 criteria. Due to relatively low 
sensitivity, classification criteria are not an appropriate di-
agnostic tool in routine clinical setting. Their primary pur-
pose is defining homogeneous patient cohorts for clinical 
research. Therefore, the gold standard for diagnosing most 
of rheumatic diseases, including SLE, remains an experi-
enced rheumatologist’s assessment. The results of this re-
search contribute to the ongoing initative for developing 
improved classification criteria for SLE (41).
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